Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00337662 · ClinicalTrials.gov registry record · Phase 4
Efficacy Study of Early Onset of Antipsychotic Drug Action in Schizophrenia
A Phase 4 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 628
- Enrollment target
NCT00337662: Completed Phase 4 study, sponsored by Eli Lilly and Company.
NCT00337662 is a Phase 4 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 628 participants, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (21% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00337662, a Phase 4 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 628 participants
- Enrollment target
Study Summary
The current study has been designed to address the significance of early onset of response prospectively in patients treated with an atypical antipsychotic.
Primary Outcome
Assesses positive symptoms, negative symptoms, and general psychopathology specifically associated with schizophrenia. Scale consists of 30 items. Each item is rated on a scale from 1 (symptom not present) to 7 (symptoms extremely severe). Sum of 30 items is PANSS total score and ranges from 30 to 210. Change = time point - single-blind baseline (Week 0).
Interventions
- DRUG risperidone
- DRUG olanzapine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 628 participants |
| Start Date | 2006-05 |
| Est. Completion | 2007-12 |
| Phase | Phase 4 |
What the finished NCT00337662 record still lists
NCT00337662 is an interventional study that assigns participants to a tested intervention. The registered 628 participants enrollment target is mid-sized for trials with a published cap, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (21% higher).
The record links to 0 conditions, and to 2 interventions - of which risperidone is the first listed.
NCT00337662 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00337662 about?
NCT00337662 is a clinical study titled "Efficacy Study of Early Onset of Antipsychotic Drug Action in Schizophrenia". The current study has been designed to address the significance of early onset of response prospectively in patients treated with an atypical antipsychotic.
What is the current status of trial NCT00337662?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 628 participants. The study started on 2006-05. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00337662?
The interventions under investigation include: risperidone (DRUG), olanzapine (DRUG).
Who is sponsoring clinical trial NCT00337662?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00337662's enrollment target sits among peer trials
628 130th of 2000 higher than 1,871 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04704921 · 630 participants · Phase 2
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD
- NCT04707729 · 630 participants · NA
ROX Index for the Timing of Intubation in Nasal High Flow
- NCT05061550 · 630 participants · Phase 2
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
- NCT05224440 · 630 participants · NA
National Sponsorship Program for Transitioning Service Members
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia